Anabolic steroidAndrogenInjectableDihydrotestosterone derivative

Methenolone Caproate

Also known as Primobolan caproate · Methenolone hexanoate

Written by enwyReviewed 5 Aug 20261 sources0 comments

A medium-acting caproate (hexanoate) ester of methenolone, sitting between the short acetate and long enanthate esters of the mild Primobolan parent. The caproate ester would give a release duration slightly shorter than enanthate, useful for smoothing blood levels of this gentle, non-aromatising DHT derivative. It has essentially no pharmaceutical history and is a niche underground ester.

01 Overview

Methenolone is a mild, non-aromatising, non-17-alpha-alkylated androgen used for lean mass preservation. Its established esters are acetate (oral/short injectable) and enanthate (Primobolan Depot). A caproate ester falls in between in chain length, giving intermediate release kinetics.

There is no pharmaceutical or veterinary methenolone caproate, so no pharmacokinetic study exists for it. Its expected profile is identical to methenolone with a medium-duration ester: gentle anabolism, no estrogenic activity, low hepatotoxicity and moderate suppression. It is included to round out the injectable methenolone-ester family and is uncharacterised in humans.

02 Mechanism

Methenolone is a mild, non-aromatising androgen receptor agonist; the caproate ester is hydrolysed at an intermediate rate to give medium-duration release.

03 Dosing

Tier	Dose	Route	Notes
Common	300–500 mg/wk	IM	Anecdotal; extrapolated from methenolone enanthate dosing.
High	500–700 mg/wk	IM	Cost and mildness usually limit high dosing.

Ester comparison

Ester	Half-life	Injection freq.	Testosterone by mass

04 Effects

Effect	Magnitude	Evidence
Lean mass preservationLike other methenolone esters, valued for holding muscle while cutting.	Muscle retention in a deficit	Observational
Non-estrogenic profileNo estrogenic water retention or gynecomastia.	No aromatisation	Clinical

05 Side effects

Effect	Severity	Frequency	Evidence
Mild androgenic effectsAcne or hair thinning possible but less likely than with stronger androgens.	Mild	Uncommon	Observational
Injection-site reactionOil-based injections can occasionally irritate the site.	Mild	Uncommon	Anecdotal
HPTA suppressionSuppresses natural testosterone despite mildness.	Moderate	Universal at cycle doses	Observational

06 Legal status

United Kingdom

Class C controlled drug

as of Jan 2026

United States

Schedule III controlled substance

as of Jan 2026

07 References

Methenolone (Primobolan) pharmacologyPharmacology reference

08 Discussion0 comments

Create account

Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.

This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.